SCHEMBL6622288

SCHEMBL6622288

CCCC[Sn](CCCC)(CCCC)c1cn2cnc(SC3CCN(C(=O)OCc4ccc([N+](=O)[O-])cc4)CC3)c2s1

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.35
KMT2A Q03164 3/20 0.35
ALDH1A1 P00352 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
LMNA P02545 1/20 0.35
MAPT P10636 1/20 0.35
GRIN2B Q13224 4/20 0.34
HRH2 P25021 1/20 0.34
HRH1 P35367 1/20 0.34
FAAH O00519 1/20 0.34
MGLL Q99685 1/20 0.34
KDM4E B2RXH2 1/20 0.34
JAK2 O60674 1/20 0.33
JAK1 P23458 1/20 0.33
TYK2 P29597 1/20 0.33
JAK3 P52333 1/20 0.33
GAA P10253 1/20 0.33
MEN1 O00255 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6623727 0.96 L3MBTL1 (0.34) L3MBTL1KMT2AALDH1A1SMN1; SMN2LMNA
SCHEMBL5231605 0.86 KMT2A (0.36) L3MBTL1KMT2AALDH1A1SMN1; SMN2LMNA
SCHEMBL5231403 0.80 PRCP (0.37) L3MBTL1KMT2AALDH1A1SMN1; SMN2LMNA
SCHEMBL7118650 0.80 L3MBTL1 (0.37) L3MBTL1KMT2AALDH1A1MAPTMEN1
SCHEMBL6624714 0.79 DPP8 (0.38) L3MBTL1KMT2AALDH1A1MAPTMGLL
SCHEMBL6623462 0.79 GRIN2B (0.38) L3MBTL1KMT2AALDH1A1SMN1; SMN2LMNA
SCHEMBL6623421 0.78 DPP8 (0.39) L3MBTL1KMT2AALDH1A1MAPTMGLL
SCHEMBL6772613 0.78 L3MBTL1 (0.36) L3MBTL1ALDH1A1MAPT
SCHEMBL7487246 0.76 GRIN2B (0.36) L3MBTL1KMT2AALDH1A1SMN1; SMN2LMNA
SCHEMBL6893539 0.76 L3MBTL1 (0.37) L3MBTL1KMT2AALDH1A1MAPTMGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6825187-B2 CARBAPENEM DERIVATIVES SUBSTITUTED AT THE 2-POSITION WITH A SUBSTITUTED IMIDAZO(5,1-B)THIAZOLE GROUP; USE AGAINST ANTIBIOTIC RESISTANT STAPHYLOCOCCUS AUREUS AND PSEUDOMONAS AERUGINOSA, ENTEROCOCCI AND INFLUENZA VIRUS MEIJI SEIKA KAISHA, LTD. (JP) 2004-11-30 US disclosed
EP-1251133-B1 NOVEL CARBAPENEM DERIVATIVES MEIJI SEIKA KAISHA (JP) 2004-10-13 EP disclosed
US-6680313-B2 1-HYDROXYETHYL-2(IMIDAZO(5,1B)THIAZOL-2-YL-1-CARBAPEN-2-EM-3-C CARBOXYLIC ACID OR SALT, EXCELLENT ANTIBIOTIC ACTIVITY AGAINST A WIDE SPECTRUM OF BACTERIA MEIJI SEIKA KAISHA, LTD. (JP) 2004-01-20 US disclosed
US-20030027809-A1 Novel carbapenum derivatives MEIJI SEIKA KAISHA, LTD. (JP) 2003-02-06 US disclosed
US-20030022881-A1 Novel carbapenem derivatives of quarternary salt type MEIJI SEIKA KAISHA, LTD. (JP) 2003-01-30 US disclosed
EP-1251134-A1 NOVEL CARBAPENEM DERIVATIVES OF QUATERNARY SALT TYPE MEIJI SEIKA KAISHA LTD. (JP) 2002-10-23 EP disclosed
EP-1251133-A1 NOVEL CARBAPENEM DERIVATIVES MEIJI SEIKA KAISHA LTD. (JP) 2002-10-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030027809-A1 Novel carbapenum derivatives DHPS, DPEP1, OXA1L L3MBTL1 1185/4885KMT2A 733/4885ALDH1A1 260/4885
US-20030022881-A1 Novel carbapenem derivatives of quarternary salt type DHPS, HDHD5, RRP15 L3MBTL1 1186/4885KMT2A 562/4885ALDH1A1 518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.